FDA Approves Supplemental Application for SYNJARDY by Boehringer Ingelheim
The FDA has approved a supplemental application for SYNJARDY (NDA206111), containing empagliflozin and metformin hydrochloride, submitted by Boehringer Ingelheim.
Asset / Drug
Drug and asset intelligence for SYNJARDY with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
SGLT2 Inhibitor
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.